The Potential of Dutasteride for Treating Multidrug-Resistant Candida auris Infection
Novel antifungal drugs are urgently needed to treat candidiasis caused by the emerging fungal multidrug-resistant pathogen . In this study, the most cost-effective drug repurposing technology was adopted to identify an appropriate option among the 1615 clinically approved drugs with anti- activity....
Gespeichert in:
Veröffentlicht in: | Pharmaceutics 2024-06, Vol.16 (6), p.810 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Novel antifungal drugs are urgently needed to treat candidiasis caused by the emerging fungal multidrug-resistant pathogen
. In this study, the most cost-effective drug repurposing technology was adopted to identify an appropriate option among the 1615 clinically approved drugs with anti-
activity. High-throughput virtual screening of 1,3-beta-glucanosyltransferase inhibitors was conducted, followed by an analysis of the stability of 1,3-beta-glucanosyltransferase drug complexes and 1,3-beta-glucanosyltransferase-dutasteride metabolite interactions and the confirmation of their activity in biofilm formation and planktonic growth. The analysis identified dutasteride, a drug with no prior antifungal indications, as a potential medication for anti-
activity in seven clinical
isolates from Saudi Arabian patients. Dutasteride was effective at inhibiting biofilm formation by
while also causing a significant reduction in planktonic growth. Dutasteride treatment resulted in disruption of the cell membrane, the lysis of cells, and crushed surfaces on
, and significant (
-value = 0.0057) shrinkage in the length of
was noted at 100,000×. In conclusion, the use of repurposed dutasteride with anti-
.
potential can enable rapid recovery in patients with difficult-to-treat candidiasis caused by
and reduce the transmission of nosocomial infection. |
---|---|
ISSN: | 1999-4923 1999-4923 |
DOI: | 10.3390/pharmaceutics16060810 |